Reduction of Hip2 suppresses gastric cancer cell proliferation, migration, invasion and tumorigenesis

Jugang Wu†, Baoxing Tian†, Jianjun Yang, Haizhong Huo, Zhicheng Song, Jiwei Yu, Yan Gu

Department of General Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Contributions: (I) Conception and design: J Wu; (II) Administrative support: Y Gu; (III) Provision of study materials or patients: Y Gu, J Yu; (IV) Collection and assembly of data: J Wu, B Tian; (V) Data analysis and interpretation: J Wu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

†These authors contributed equally to this work.

Background: Hip2, a ubiquitin-conjugating enzyme, has been shown to modulate the stability of cyclin B1, a cell cycle regulator. However, the function of Hip2 in gastric cancer (GC) remains largely elusive.

Methods: The expression of Hip2 in GC cell lines was analyzed by RT-qPCR, Western Blotting and Immunohistochemical Staining. shRNA was utilized to knock down the expression of Hip2. Cell growth, cell cycle, migration, invasion and tumorigenesis were performed by CCK-8, BrdU staining, flow cytometry, wound healing, transwell migration and invasion, and xenograft assay, respectively.

Results: Hip2 was highly expressed in GC cell lines and patients. High level of Hip2 indicated poor prognosis. Knockdown of Hip2 suppressed cell growth, lead to G2/M phase arrest, and reduced cell migration and invasion in vitro. Furthermore, downregulation of Hip2 inhibited tumorigenesis in vivo.

Conclusions: Elevated expression of HIP2 in GC patients suggested poor prognosis. Reduction of Hip2 suppressed GC progression, indicating that Hip2 may be a potential target for the management of GC.

Keywords: Hip2; gastric cancer (GC); proliferation; migration and invasion; tumorigenesis

Submitted Aug 15, 2019. Accepted for publication Nov 15, 2019.


View this article at: https://dx.doi.org/10.21037/tcr.2019.12.12

Introduction

Gastric cancer (GC) is the sixth most common malignancy and the second leading cause of cancer-related death worldwide (1). In China, the new cases of GC were 679,100 and the GC-related deaths were 498,000 in 2015 (2). In comparison to females (new cases 477,700 in 2015), males (new cases 201,400 in 2015) are much more vulnerable to GC (2). The high capability of invasion and metastasis in GC patients largely accounts for the poor prognosis. However, there is currently no effective method for the successful treatment of progressive or metastatic GC. Therefore, finding a protein that regulates cell apoptosis, growth arrest, and the migration and invasion behavior of GC cells is a prerequisite for the development of new therapies.

Hip2 (short for huntingtin interacting protein 2), a protein associated with Huntington's disease, was first discovered in a yeast two-hybrid screen who interacts with huntingtin (3). It is also named as E2-25K, a ubiquitin-conjugating (E2) enzyme, and has been shown to be involved in the mediation of amyloid-β neurotoxicity and inhibition of proteasome in vitro (4). It functions as a part of machinery of the ubiquitin/proteasome system (UPS). The UPS is involved in a variety of biological pathways. For example, it regulates the cell cycle and modulates the degradation of short-lived and regulatory proteins (5-7). It has been reported that Hip2 can regulate the stability of cyclin B1, a apoptotic and cell cycle regulator, by promoting...
its degradation (8). However, the function of HIP2 in GC remains largely unclear.

In the current study, we analyzed the expression of Hip2 in GC cell lines and patients, and illuminated the role of Hip2 in GC progression. The results showed that the expression of Hip2 was high in human GC and positively correlated with clinical pathology, indicating that Hip2 contributes to high malignancy of GC and poor prognosis. Knockdown of Hip2 significantly inhibited the proliferation, migration and invasion of GC cells in vitro, and reduced tumorigenesis in vivo.

Methods

Patients and tumor specimens

Between Jan. 1, 2006 and Dec. 31, 2007, a total of 76 patients (48 males and 28 females) diagnosed with gastric adenocarcinoma registered for the current study. The patients ranged from 30 to 81 years old (median age = 64) and were all hospitalized at the Department of General Surgery, No. 9 People’s Hospital, Shanghai Jiao Tong University School of Medicine. Among the patients, 9 experienced total gastrectomy, 57 underwent distal subtotal gastrectomy, and 10 had proximal subtotal gastrectomy. In addition, D1 lymphadenectomy, D2 lymphadenectomy, and D3 lymphadenectomy was performed on another 2, 68, and 6 patients, respectively. Postoperative pathological examination revealed 13 cases of early adenocarcinoma, 3 cases of fungal adenocarcinoma, 10 cases of ulcerative adenocarcinoma, 41 cases of invasive ulcerated adenocarcinoma, and 9 cases of diffuse invasive adenocarcinoma. Patient follow-up ended on Dec. 31, 2017, with a median follow-up of 30 months. During this period, 45 patients died of recurrence or metastasis and 16 patients died of other diseases. The survival time ranged from 3 to 130 months.

Tumor tissues after radical surgery were embedded in paraffin and stained with Hip2. The relationships between Hip2 expression and clinicopathological characteristics, survival time after surgery were analyzed respectively. Furthermore, another 20 patients of chronic gastritis (GS) and 20 patients of gastric ulcer (GU) diagnosed by gastroscopic biopsies were enrolled as negative control.

All patients with GC in this study underwent curative gastrectomy, and none of them received preoperative chemotherapy or radiation therapy. A preoperative informed consent was signed by each participating patient according to institutional guidance. All clinicopathological profiles were assessed according to the 8th edition criteria of the American Joint Committee on Cancer (AJCC) (9) and ESMO Clinical Practice Guidelines (10). Prior to the study, approval was obtained from the hospital Review Board and the Ethics Committee of the Medical Faculty at the Shanghai Jiao Tong University.

Immunohistochemistry (IHC) staining

Four μm serial tissue sections were prepared and then deparaffinized, rehydrated with graded ethanol. Three percent hydrogen peroxide was utilized to block endogenous peroxidase, and 10 mM citrate buffer (pH 6.0) was used to retrieve antigen. Then 5% goat serum was used to block the tissue sections at room temperature for 1 hour. Hip2 mAb (1:100, Abcam, UK) was diluted in the blocking solution. The slides were then rinsed and incubated with Hip2 overnight at 4 °C, and then incubated at room temperature for 1 hour with the appropriate biotinylated secondary antibody (1:1,000, Boster, China). After this washing series, avidin/biotinylated HRP were used to incubate the tissues (ABC kit, Santa Cruz Biotechnology, USA) in accordance with the manufacturer’s instructions. The slides were immersed in diaminobenzidine (DAB)/H2O2 substrate solution until the desired staining intensity was achieved. Following this procedure, the slides were counterstained with hematoxylin. For each patient, two independent pathologists who were blind to the patient’s status were invited to evaluate and score all the sections. The evaluation of staining result was scored as previously described (11,12). Then the staining cell scores (0 point = 0–5%; 1 point = 6–25%; 2 points = 26–50%; 3 points = more than 50%) and staining intensity scores (0 point = negative; 1 point = weak intensity; 2 points = moderate intensity; 3 points = strong intensity) were summed to obtain a composite score. A score with ≥4 points meant high positive, a score with ≤3 points and ≥2 indicated low positive, and a score with ≤1 point represented negative.

Bioinformatic analysis of clinical data

GC dataset was obtained from The Cancer Genome Atlas (TCGA) database. Analysis of Hip2 expression was performed using GEPIA (Gene Expression Profiling Interactive Analysis) (http://gepia.cancer-pku.cn). Overall survival of patients with stomach adenocarcinoma (STAD)
was assessed by KM plotter: Kaplan-Meier Plotter (http://kmplot.com/analysis/).

**Cell lines**

The human GC cell lines AGS, BGC823, MCG803, MKN28, MKN45, and SGC7901, along with the human normal gastric cell lines GES-1, were purchased from American Type Culture Collection (ATCC, USA). In accordance with the manufacturer's instructions, all the cells were cultured in RPMI-1640 (HyClone) supplemented with 10% fetal bovine serum (Gibco). All cell lines were kept in a humid atmosphere of 37 °C with 5% CO₂.

**Establishment of stable Hip2 knockdown cell lines**

A scrambled sequence and Hip2 targeting sequence were constructed into the lentiviral expression vector pLKO.1 to obtain control and lenti-shHip2 plasmid. The scrambled sequence is 5'-UUCUCCGAACGUGUCACGU-3', and Hip2 targeting sequence is 5'-GGUCCGGUUAU CACUAAATT-3'. Recombinant lentiviruses expressing corresponding Hip2-shRNA were subsequently produced via co-transfection of lenti-shHip2, helper plasmid psPAX2 and VSV G expressing plasmid pMD2.G on 293T cells with Lipofier (HanBio, Shanghai, China). Forty-eight hours after the transfection, the cultured supernatant was collected, filtered, and concentrated by ultracentrifugation. The viruses were used to infect MKN45 and AGS cell lines to establish stable Hip2-knockdown cell lines. Seventy-two hours after the infection, the cells were treated with 1 μg/mL puromycin. Clones resistant to puromycin were selected and expanded for use in subsequent experiments.

**Real time-qPCR**

In accordance with the manufacturer's instructions, TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from GC cells. A RevertAid™ First Strand cDNA Synthesis kit (Takara) was utilized to conduct reverse transcription, and a QuantiTect SYBR Green kit (Biotool, Houston, TX, USA) was used to perform qPCR. The relative expression levels of mRNA were first normalized to the expression levels of GAPDH, after which they were determined via the comparative Ct-method. For the analysis of gene expression levels, each gene was subjected to the analysis three times. The primer sequences for Hip2 were 5'-GTTCCGTCACAGGGGCTATTT-3' (forward) and 5'-AATACCGTGCGGAGAGTCATT-3' (reverse).

**Western blot**

Lysis buffer radioimmunoprecipitation assay (RIPA) (Beyotime Institute of Biotechnology, China) containing protease inhibitors phenylmethanesulfonyl fluoride (PMSF) (Beyotime Institute of Biotechnology, China) was used to dissolve the cells and tissues. Bicinchoninic acid (BCA) protein assay kit (Beyotime Institute of Biotechnology, China) was utilized to determine the protein concentration. Equal amounts of protein (20 μg) in 10 μL volume were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, USA). The cell membranes were blocked with 5% non-fat milk and then incubated with primary antibodies overnight at 4 °C. Incubation with secondary antibodies was performed at room temperature for 1 h. To visualize the protein bands, the enhanced chemiluminescence detection kit (Thermo scientific, USA) was used. The primary antibodies were: Hip2 mAb (1:2,000, Abcam, UK), and GAPDH (1:5,000, Bioworld Technology, USA).

**Cell viability assay**

To detect cell growth, cells were seeded at a density of 3×10⁴ cells per well in 96-well plates and grown for a specified period of time. At the end of the period, 10 μL of cell counting kit-8 (CCK-8, Dojindo, Japan) solution was added to each well, where the cells were incubated at 37 °C for another 80 min. Absorbance readings were measured using a 450 nm plate reader. The impact of background absorbance was eliminated to obtain cell viability.

**Cell proliferation assay**

To perform BrdU staining, cells were first immersed in BrdU (1 mg/mL) for 4 h, and then fixed with acid ethanol (90% ethanol, 5% acetic acid, 5% H₂O₂) at room temperature for 30 min. Subsequently, cells were rinsed once with PBS, submerged in 2 M HCl for 20 min, 0.1 M sodium borate, pH 8.5 for 2 min and rinsed once with PBS. At room temperature, cells were blocked for 1 hour in 10% BSA in PBS and immersed in anti-BrdU (BD Pharmingen, 1:500 in 5% BSA in 0.1% PBS Tween) at 4 °C. Cells were
rinsed, submerged in anti-mouse Alexa-594 (1:500) at room temperature for 1 h, washed, co-stained with DAPI and mounted.

**Cell cycle analysis**

Different types of single cell suspension were prepared and fixed in 70% ethanol at 4 °C for 4 h. They were then subjected to treatment with 10 mg/mL RNase at room temperature for 30 min. After 10 μL of propidium iodide (PI, 5 mg/mL) was added, the samples were incubated at room temperature for 10 min and analyzed with a FACS (BD Bioscience Mountain View, CA, USA).

**Wound-healing assay**

Cells were cultured at 80–90% confluence in six-well plates. Ten-μL plastic tips were used to scrape the wound areas to form a straight line. Culture plates were washed three times to remove cell debris and changed to the serum-free medium. An inverted research microscope eclipse TS100/100-F (Nikon, Japan) was used to monitor the healing process by taking images every 24 h. The healing rate = (0–48 h width)/0 h width.

**Transwell migration and invasion**

To perform migration assay, a 24-well 8-μm pore size transwell chamber (Corning, USA) was used. The bottom of the transwell chamber was coated with BD Matrigel™ Matrix Basement Membrane (BD Biosciences, USA) to measure cell invasion. 1×10⁵ cells were immersed in 200 μL serum free medium in the upper chamber, while the lower chamber was filled with 600 μL medium containing 20% fetal bovine serum as a chemoattractant. The incubation process lasted for 48 h, after which the non-invading cells on the upper surface of the membrane were scraped away. Invading cells on the lower side of the membrane were fixed in 4% paraformaldehyde and stained with 0.05% crystal violet. A microscope was used to record the number of invasive cells. These experiments were performed in triplicate.

**Xenograft tumor**

Male nude athymic BALB/c mice (S, China) of approximately four weeks were obtained from SLAC Laboratory Animal Co., Ltd. (Shanghai, China). The mice were subcutaneously injected with 5×10⁶ cells from the shCtrl or shHip2 group in 0.2 mL volume in their right flanks, respectively. This was followed by measurements of the tumors size every three days. The formula used for the measurement of tumor size was: volume = (length × width²)/2. At the end of the experiment, the mice were killed. Their tumor was then weighted and fixed in 10% neutral-buffered formalin. All the experimental procedures complied with Shanghai Jiao Tong University guidelines for the use of animals, and were approved by The Animal Care and Utilization Committee of Shanghai Jiao Tong University.

**Statistical analysis**

Results are presented as means ± SD. Chi-square analysis was performed to estimate clinicopathological parameters. The Kaplan-Meier method was used to obtain survival curves, and survival rate was analyzed using the log-rank method. For cell and animal experiments, the data were submitted to one-way ANOVA or Student's t test. All the analyses were performed using Graphpad Prism 8.0 software (Graphpad Software; San Diego, CA, USA), and P values of <0.05 indicated that the results were statistically significant.

**Results**

**Hip2 expression was elevated in GC cancer cell lines and tissues**

To illuminate the function of Hip2 in human GC progression, we firstly recorded Hip2 expression in GC cell lines (gastric carcinoma cell lines MGC-803 and SGC-7901, and gastric adenocarcinoma cell line BGC-823, MKN28, MKN45 and AGS) and gastric epithelial cell line GES-1. The levels of mRNA (Figure 1A) and protein (Figure 1B) in Hip2 are higher in GC cell lines than those in epithelial cell line. Next, we investigated the expression profile of Hip2 in human GC tissues. The samples comprised 116 patients, including 20 patients with GS, 20 with GU, and 76 with GC. A summary of the patient data is presented in Table 1. The protein levels of Hip2 in GC specimens were examined by immunohistochemical staining. All the specimens were categorized into three groups (negative, low positive and high positive) according to the expression score based on the density and percentage of IHC staining. All GS patients belong to negative group, 15% (3/20) in patients with
GU belong to low positive group and the others belong to negative group, and 28.9% (22/76) in patients with GC belong to low positive group and the others belong to high positive group. The expression of HIP2 was 0% (0/20) in patients with GS, 15% (3/20) in patients with GU, and 100% (76/76) in patients with GC (Figure 1C,D). Furthermore, the data from TCGA shown that the mRNA levels of Hip2 in STAD were remarkably higher than that in normal gastric tissues (Figure 1E). These data indicated that the elevated Hip2 may promote GC progression.

**High levels of Hip2 predicted poor prognosis in GC patients**

To explore the correlation between clinicopathological features of GC patients and the levels of their Hip2 expression, we evaluated various key parameters for tumors from patients, including tumor size, lymphatic vessel invasion (LVI), T stage, lymph node metastasis, metastatic lymph nodes ratio, and TNM stage (Table 1). Strikingly, Hip2 expression levels were significantly correlated with tumor size (P≤0.012), LVI (P≤0.003), T stage (P≤0.001), lymph node metastasis (P≤0.001), metastatic lymph nodes ratio (P≤0.001) and pTNM stage (P≤0.001), respectively. But no significant correlation was found for gender (P=0.956), histology type (P=0.346) or venous invasion (P=0.065) (Table 1). The overall survival rate in Hip2 low positive group was higher than that in Hip2 high positive group (Figure 2A). The five-year and ten-year survival rate...
of GC patients in Hip2 high positive group were 27.3% and 23.1% respectively, compared with that of 70.8% and 64.3% in Hip2 low positive group in GC (Figure 2A and Table 1). The data from TCGA also showed that the overall survival rate was lower in the patients who exhibit high levels of Hip2 expression in STAD (Figure 2B). These results indicate that the patients who expressed high levels of Hip2 predicted poor prognosis.

Table 1 Distribution of clinical characteristics stratified by Hip2 protein expression in 76 patients with GC

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Group</th>
<th>Samples (n)</th>
<th>Hip2 expression (n/%)</th>
<th>P value</th>
<th>Long-term survival (%)</th>
<th>Log-rank (χ² value)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Low positive</td>
<td>High positive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>48</td>
<td>14 (29.2)</td>
<td>34 (70.8)</td>
<td>0.956</td>
<td>39.2</td>
<td>32.0</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>28</td>
<td>8 (28.6)</td>
<td>20 (71.4)</td>
<td>0.102</td>
<td>41.2</td>
<td>41.2</td>
</tr>
<tr>
<td>Age (years)</td>
<td>≥60</td>
<td>52</td>
<td>14 (26.9)</td>
<td>38 (73.1)</td>
<td>0.569</td>
<td>35.1</td>
<td>28.1</td>
</tr>
<tr>
<td></td>
<td>&lt;60</td>
<td>24</td>
<td>8 (33.3)</td>
<td>16 (66.7)</td>
<td>0.641</td>
<td>47.9</td>
<td>47.9</td>
</tr>
<tr>
<td>Tumor diameter (cm)</td>
<td>≥5</td>
<td>38</td>
<td>6 (15.8)</td>
<td>32 (84.2)</td>
<td>0.012</td>
<td>8.5</td>
<td>4.2</td>
</tr>
<tr>
<td></td>
<td>&lt;5</td>
<td>38</td>
<td>16 (42.1)</td>
<td>22 (57.9)</td>
<td>0.122</td>
<td>72.2</td>
<td>67.8</td>
</tr>
<tr>
<td>Histology</td>
<td>1–2</td>
<td>20</td>
<td>5 (25.0)</td>
<td>15 (75.0)</td>
<td>0.652</td>
<td>57.2</td>
<td>57.2</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>56</td>
<td>17 (30.4)</td>
<td>39 (69.6)</td>
<td>0.282</td>
<td>33.6</td>
<td>28.1</td>
</tr>
<tr>
<td>Lauren’s classification</td>
<td>Intestinal</td>
<td>51</td>
<td>13 (25.5)</td>
<td>38 (74.5)</td>
<td>0.346</td>
<td>45.6</td>
<td>42.2</td>
</tr>
<tr>
<td></td>
<td>Diffuse</td>
<td>25</td>
<td>9 (36.0)</td>
<td>16 (64.0)</td>
<td>0.282</td>
<td>28.5</td>
<td>22.1</td>
</tr>
<tr>
<td>Lymphatic vessel invasion</td>
<td>Negative</td>
<td>38</td>
<td>17 (44.7)</td>
<td>21 (55.3)</td>
<td>0.003</td>
<td>62.8</td>
<td>59.0</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>38</td>
<td>5 (13.2)</td>
<td>33 (86.8)</td>
<td>0.169</td>
<td>16.9</td>
<td>8.5</td>
</tr>
<tr>
<td>Venous invasion</td>
<td>Negative</td>
<td>63</td>
<td>21 (33.3)</td>
<td>42 (66.7)</td>
<td>0.065</td>
<td>44.1</td>
<td>39.2</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>13</td>
<td>1 (7.7)</td>
<td>12 (92.3)</td>
<td>0.576</td>
<td>17.6</td>
<td>/</td>
</tr>
<tr>
<td>Depth of invasion</td>
<td>pT1</td>
<td>13</td>
<td>10 (76.9)</td>
<td>3 (23.1)</td>
<td>0.000</td>
<td>92.3</td>
<td>92.3</td>
</tr>
<tr>
<td></td>
<td>pT2</td>
<td>14</td>
<td>5 (35.7)</td>
<td>9 (64.3)</td>
<td>0.000</td>
<td>77.9</td>
<td>62.3</td>
</tr>
<tr>
<td></td>
<td>pT3</td>
<td>7</td>
<td>1 (14.3)</td>
<td>6 (85.7)</td>
<td>0.012</td>
<td>57.1</td>
<td>57.1</td>
</tr>
<tr>
<td></td>
<td>pT4</td>
<td>42</td>
<td>6 (14.3)</td>
<td>36 (85.7)</td>
<td>0.000</td>
<td>8.0</td>
<td>5.3</td>
</tr>
<tr>
<td>LNM</td>
<td>N0</td>
<td>28</td>
<td>16 (57.1)</td>
<td>12 (42.9)</td>
<td>0.000</td>
<td>84.6</td>
<td>79.2</td>
</tr>
<tr>
<td></td>
<td>N1</td>
<td>8</td>
<td>1 (12.5)</td>
<td>7 (87.5)</td>
<td>0.000</td>
<td>37.5</td>
<td>37.5</td>
</tr>
<tr>
<td></td>
<td>N2</td>
<td>14</td>
<td>2 (14.3)</td>
<td>12 (85.7)</td>
<td>0.000</td>
<td>16.8</td>
<td>8.4</td>
</tr>
<tr>
<td></td>
<td>N3</td>
<td>26</td>
<td>3 (11.5)</td>
<td>23 (88.5)</td>
<td>0.000</td>
<td>4.7</td>
<td>/</td>
</tr>
<tr>
<td>pTNM</td>
<td>I</td>
<td>21</td>
<td>15 (71.4)</td>
<td>6 (28.6)</td>
<td>0.000</td>
<td>90.5</td>
<td>82.9</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>13</td>
<td>1 (7.7)</td>
<td>12 (92.3)</td>
<td>0.000</td>
<td>73.0</td>
<td>73.0</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>42</td>
<td>6 (14.3)</td>
<td>36 (85.7)</td>
<td>0.000</td>
<td>5.1</td>
<td>0</td>
</tr>
<tr>
<td>Metastatic lymph nodes ratio</td>
<td>MLR1</td>
<td>28</td>
<td>16 (57.1)</td>
<td>12 (42.9)</td>
<td>0.000</td>
<td>84.6</td>
<td>79.2</td>
</tr>
<tr>
<td></td>
<td>MLR2</td>
<td>11</td>
<td>1 (9.1)</td>
<td>10 (90.9)</td>
<td>0.000</td>
<td>36.4</td>
<td>36.4</td>
</tr>
<tr>
<td></td>
<td>MLR3</td>
<td>37</td>
<td>5 (13.5)</td>
<td>32 (86.5)</td>
<td>0.000</td>
<td>6.6</td>
<td>0</td>
</tr>
<tr>
<td>Hip2 expression</td>
<td>Low</td>
<td>24</td>
<td>/</td>
<td>/</td>
<td>0.000</td>
<td>70.8</td>
<td>64.3</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>52</td>
<td>/</td>
<td>/</td>
<td>0.000</td>
<td>27.3</td>
<td>23.1</td>
</tr>
</tbody>
</table>
Knockdown of Hip2 inhibited GC cell proliferation

To clarify the role of Hip2 in GC cell proliferation, short hairpin RNAs against Hip2 were used to knock down Hip2 expression in 2 human GC cell lines, MKN45 and AGS, because Hip2 expression is relatively higher in these two cell lines compared with other GC cell lines. The stable Hip2 knockdown MKN45 and AGS cells were established and used for following assay. Hip2 knockdown and control cells seeded into 96 well plates, and cell growth was subjected to CCK-8 assay. As shown in Figure 3A and B, knockdown of Hip2 inhibited GC cell growth in MKN45 (Figure 3A) and AGS (Figure 3B) cells. Then, BrdU staining was taken to confirm the effect of Hip2 on cell proliferation. Consistently, knockdown of HIP2 resulted in a decreased BrdU positive cells in MKN45 (Figure 3C) and AGS (Figure 3D) cells. Furthermore, cell cycle of Hip2 knockdown and control cells was analyzed by FACS. The results shown that knockdown of Hip2 induced G2/M arrest in MKN45 (Figure 3E) and AGS (Figure 3F) cells. These data indicated that reduction of Hip2 inhibited GC cell proliferation.

Knockdown of Hip2 suppressed GC cell migration and invasion

As migration and invasion are two key characteristics of cancer cells, we also measured whether knockdown of Hip2 impaired the migration and invasion of GC cells. First, the GC cells were tested for their wound healing ability. As shown in Figure 4A and B, knockdown of Hip2 decreased GC cell wound healing in MKN45 (Figure 4A) and AGS (Figure 4B) cells. Furthermore, transwell migration and invasion assay were performed to detect cell migration and invasion. We found that knockdown of Hip2 reduced the ability of MKN45 and AGS cells to pass through the basement membrane in the presence or absence of matrigel (Figure 4C,D,E,F). The Migration and invasion rates of Hip2 knockdown MKN45 and AGS cells were lower than those control cells (Figure 4C,D,E,F). Knockdown of Hip2 inhibited migration (Figure 4C) and invasion (Figure 4E) by about 15% and 70%, respectively, in MKN45 (Figure 4C,E) cells. In AGS cells, migration (Figure 4D) and invasion (Figure 4F) were suppressed by about 70% and 60%, respectively (Figure 4D,F). These data indicated that reduction of Hip2 inhibited the migration and invasion of GC cells.

Knockdown of Hip2 inhibited MKN45 cell tumorigenesis

The above results demonstrated that reduction of Hip2 suppressed the proliferation, migration and invasion of GC cells. Then, a xenograft tumor model was constructed to analyze the effects of Hip2 downregulation on GC cell tumorigenesis in vivo. Hip2 knockdown and control MKN45 cells were subcutaneously injected into nude mice. The tumors were harvested at the experimental end point, and the tumor size and weight were measured. As shown in Figure 5A and B, the tumors in Hip2 downregulation group
Figure 3 Knockdown of Hip2 suppressed the migration and invasion of GC cells. (A,B) Knockdown of Hip2 suppressed GC cell growth in MKN45 (A) and AGS (B) cells. Cell growth was recorded by CCK-8 assay. (C,D) Knockdown of Hip2 suppressed GC cell replication in MKN45 (C) and AGS (D) cells. Cell replication was performed by BrdU staining. (E,F) Knockdown of Hip2 induced GC cell G2/M arrest in MKN45 (E) and AGS (F) cells. Flow cytometry was used to analyze cell cycle. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
grew much slower and weighed much less compared with control group. The tumor volume was $1,261.0\pm224.9 \text{ mm}^3$ in the shCtrl group and $369.2\pm150.0 \text{ mm}^3$ in the shHip2 group, the tumor weight was $0.5619\pm0.0635 \text{ g}$ in the shCtrl group and $0.1797\pm0.0449 \text{ g}$ in the shHip2 group, respectively. There were less inflammatory cells infiltrated in shHip2 group tumor compared to shCtrl group (Figure 5C).

As expected, expression of Hip2 performed by IHC went an apparent decline in the xenograft tumors of shHip2 group (Figure 5D). These data indicated that reduction of Hip2 suppressed tumorigenesis.

**Discussion**

In the present work, we clearly demonstrate the key role of Hip2 in GC progression: (I) a obviously up-regulation of Hip2 in GC was identified by analyzing the data which obtained from our enrolled specimens and TCGA dataset; (II) knockdown of Hip2 significantly reduced the proliferation, migration and invasion of GC cells; and (III) knockdown of Hip2 suppressed GC tumorigenesis.

Hip2, a human homolog of the Ubc1 enzyme of *S. cerevisiae*, is a ubiquitin-conjugating enzyme encoded
by the UBE2K gene (13). Besides acting as an E2 conjugating enzyme, HIP2 also has basal E3-independent polyubiquitination activity, which is involved in UPS-mediated protein degradation (14,15). Protein degradation by the UPS is carried out through two successive steps: ubiquitination and degradation. Ubiquitination is achieved by a cascade of enzymes that activate (E1), conjugate (E2) and ligate (E3) ubiquitin to target proteins. In the ubiquitination of proteins to be degraded, E2 proteins play an integral role by interacting specifically with a subset of E3 and targeting proteins. Furthermore, Hip2 is a special type of E2 because it not only functions as the E2 conjugating enzyme, but also has UBA domains that produce an unanchored Lys48-polyubiquitin chain and

Figure 5 Knockdown of Hip2 inhibited MKN45 GC cells tumorigenesis. (A,B) The size and weight of subcutaneous tumor in shCtrl and shHip2 group; (C) the HE staining of xenograft tumors in shCtrl and shHip2 group; (D) the expression of Hip2 in tumors sections of shCtrl and shHip2 group were determined by IHC. *, P<0.05; **, P<0.01.
ubiquitinate substrates without ubiquitin ligases (14,15). Previously, Bae et al. reported that Hip2 promoted cyclin B1 degradation through the ubiquitin proteasome pathway (8). Cyclin B1 is artificially controlled, and helpful for mitotic exit and completion of the cell cycle. We speculate that Hip2 might be involved in the mediation of cell cycle and the regulation of cell proliferation. As the results of this study, Hip was elevated in GC and suppressed GC cell growth in vitro (Figure 3) and in vivo (Figure 5). Migration and invasion are two key characteristics of cancer cells. The protein which can control cancer cell migration and invasion are useful therapies in the treatment of cancer. As the data shown in Figure 4 suggest, we also demonstrated that knockdown of Hip2 impaired GC cell migration and invasion.

Conclusions

This study confirmed that Hip2, a ubiquitin-conjugating enzyme, was elevated in GC cells and patients. Reduction of Hip2 suppressed cell proliferation, cell cycle, wound healing, cell migration and invasion in GC cells. In this study, it was found that elevated Hip2 could promote GC progression. Therefore, Hip2 holds promise as a potential target for the treatment of GC.

Acknowledgments

Funding: This work was supported by grants of National Natural Science Foundation of China (81470792), Shanghai Shenkang Hospital Development Center (16CR4010A), and Municipal Health and Family Planning Commission of Shanghai (2016Y0255).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All the patients selected for our study were fully informed about our experimental protocols, which were approved by the Ethics Committee of the Medical Faculty at the Shanghai Jiao Tong University. All the animal experimental procedures complied with Shanghai Jiao Tong University guidelines for the use of animals, and were approved by The Animal Care and Utilization Committee of Shanghai Jiao Tong University.

